Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°
Caladrius Biosciences, Inc. (Nasdaq: CLBS) announced that Chief Medical Officer Douglas W. Losordo will participate in the 8th annual Chief Medical Officer Summit 360° on October 26-27, 2020. Losordo's breakout session titled "Tracking Personalized Medications in Gene and Cell Therapy" is scheduled for October 26 at 3:00 p.m. The company focuses on cellular therapies aimed at reversing diseases, with product candidates like CLBS119 for COVID-19 lung damage and HONEDRA® for critical limb ischemia. For more details, visit www.caladrius.com.
- None.
- None.
BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°, being held virtually on October 26-27, 2020.
Breakout Session Details:
Title: Tracking Personalized Medications in Gene and Cell Therapy
Date/Time: October 26, 2020 at 3:00 p.m.
For more information on the 8th annual CMO Summit 360°, or to register, please click here.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage in patients with COVID-19 who are experiencing respiratory failure, for which the Company recently initiated a clinical trial as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. and slated to begin a comprehensive Phase 2b trial in the U.S. during 4Q20 for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
What is the participation of Caladrius Biosciences in the CMO Summit?
What will be the topic of Douglas W. Losordo's breakout session?
What products is Caladrius currently developing?
When is CLBS16's Phase 2b trial scheduled to begin?
What designation has CLBS14 received from the FDA?
